Phase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors

Phase 2RecruitingNCT04643418

MegaPro Biomedical Co. Ltd.81 enrolled

Overview

This is a first-in-human (FIH), multicenter, open-label, uncontrolled, Phase 1/2a study with dose escalation in patients with advanced solid tumors (Part 1) and cohorts of up to 15 patients per selected indication (Part 2). The solid tumor types in Part 2 will be decided by the sponsor prior to the start of Part 2, but not be solely based on the efficacy results in Part 1.

This study will occur in two parts, Dose-escalation (Part 1) and Cohort-expansion (Part 2). The main purpose of Part 1 is to determine the doses and dosing schedule of MPB-1734 that is safe and tolerable when given in subjects with certain types of advanced cancer. Part 2 of the study will begin when the Sponsor determines the safe and tolerable doses and dosing schedule from Part 1. The main purpose of Part 2 is to continue to assess the safety and tolerability of the MPB-1734 dose and dosing schedule determined by the Sponsor during Part 1. The preliminary efficacy of MPB-1734 will also be assessed in both Part 1 and Part 2.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Solid Tumor, Unspecified, Adult

Interventions

MPB-1734DRUG

Administered once daily in a 21-day cycle

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Signed informed consent in the local language prior to any study-mandated procedure. 2. Male or female patients at least 18 years of age, at the time of informed consent. 3. Male or nonpregnant and nonlactating female patients with pathologically confirmed, measurable solid tumor lesions (Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST 1.1\]) that are unresectable, and standard therapy able to provide clinical benefit does not exist or is no longer effective. 4. Eastern Cooperative Oncology Group Performance Status ≤2. 5. Patients have recovered from the acute toxicity of previous therapies (peripheral sensory neuropathy recovered to ≤Grade 2) except alopecia, and: * At least 4 weeks have elapsed since completing surgery, endocrine therapy, tyrosine kinase inhibitor therapy, immunotherapy, radiotherapy, chemotherapy, and/or * At least 6 weeks have elapsed since completing chemotherapy with nitrosoureas, melphalan, and/or mitomycin C, and/or * At least 6 weeks have elapsed since completing cranial radiotherapy. 6. Life expectancy of greater than 12 weeks. 7. Ability to communicate well with the investigator, in the local language, and to understand and comply with the requirements of the study. Exclusion Criteria: 1. Peripheral sensory neuropathy \>Grade 2 (CTCAE version 5.0) at baseline. 2. Patients requiring immediate palliative treatment of any kind including surgery and/or radiotherapy. 3. Serum bilirubin \>1.5× ULN. 4. AST and/or ALT \>2.5× ULN if no liver involvement, OR AST and/or ALT \>5× ULN with liver involvement. 5. Serum creatinine \>1.5× ULN, and/or a creatinine clearance of \<50 mL/min calculated by Cockcroft Gault. 6. QTc prolongation defined as a QTc with Framingham correction greater than or equal to 470 ms, or significant electrocardiogram (ECG) abnormalities. 7. Known hypersensitivity to taxanes or any excipients of the drug formulation. 8. Female patients who are pregnant, breast-feeding, or planning to become pregnant during the study. 9. Untreated and/or uncontrolled central nervous system metastases. 10. Patients with brain tumors, primary or metastatic. 11. Patients taking concomitant medications anticipated to result in drug-drug interactions.

Locations (1)

Taipei Veterans General Hospital

Taipei, Taiwan

RECRUITING

Outcomes

Primary Outcomes

Evaluation the the maximum tolerated dose(MTD) by safety data

Number and incidence of (serious) adverse events (AEs) (\[S\]AEs), including rate of mild, moderate, and severe hypersensitivity reactions, fluid retention, and sensory neuropathy an adverse event or abnormal laboratory value assessed as unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the first treatment cycle.

Time frame: Through the end of the first cycle (Days 1-21).

Secondary Outcomes

Incidence of Treatment-Emergence Adverse Events

Each adverse event will be coded using the Medical Dictionary (version 20.0) system. The severity of the toxicities will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0).

Time frame: Approximately 24 weeks

Maximum observed plasma concentration (Cmax)

Evaluation the change of Cmax

Time frame: Day 1-Day 2

Area under the plasma concentration-time curve (AUC)

Evaluation the change of AUC

Time frame: Day 1-Day 2

Half-life (T1/2)

Evaluation of T1/2

Time frame: Day 1-Day 2

Central Contacts

Summer Liao, MS

CONTACT

+886-3-5910360 thliao@megaprobio.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.